1. Home
  2. MLYS vs NEXT Comparison

MLYS vs NEXT Comparison

Compare MLYS & NEXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$30.19

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo NextDecade Corporation

NEXT

NextDecade Corporation

HOLD

Current Price

$8.02

Market Cap

2.2B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
NEXT
Founded
2019
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.2B
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
MLYS
NEXT
Price
$30.19
$8.02
Analyst Decision
Strong Buy
Hold
Analyst Count
7
2
Target Price
$48.67
$8.00
AVG Volume (30 Days)
1.1M
3.1M
Earning Date
05-06-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.59
$4.75
52 Week High
$47.65
$12.12

Technical Indicators

Market Signals
Indicator
MLYS
NEXT
Relative Strength Index (RSI) 59.06 49.58
Support Level $25.88 $6.53
Resistance Level $31.12 $8.54
Average True Range (ATR) 1.45 0.44
MACD 0.22 -0.06
Stochastic Oscillator 91.67 47.26

Price Performance

Historical Comparison
MLYS
NEXT

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

Share on Social Networks: